aluates Reports

$ 0.0

Automative

Global Metabolic Disorder Therapeutics Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-27A13413

Global Metabolic Disorder Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Metabolic Disorder Therapeutics Market Research Report 2025

Code: QYRE-Auto-27A13413

Report

September 2025

Pages:90

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk A S

Sanofi

Boehringer Ingelheim GmbH

Eli Lilly and Company

Merck KGaA

Amgen Inc

Astrazeneca plc

Actelion Pharmaceuticals Ltd

Shire Plc

AbbVie

Biocon Ltd.

BioMarin Pharmaceutical Inc

Bristol Myers Squibb Company

Cipla Ltd

CymaBay Therapeutics Inc

Metabolic Disorder Therapeutics Market Size

The global market for Metabolic Disorder Therapeutics was valued at US$ 52090 million in the year 2024 and is projected to reach a revised size of US$ 69660 million by 2031, growing at a CAGR of 4.3% during the forecast period.

Metabolic Disorder Therapeutics Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Metabolic Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorder Therapeutics.

The Metabolic Disorder Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Metabolic Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Metabolic Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Metabolic Disorder Therapeutics Market Report

Report Metric	Details
Report Name	Metabolic Disorder Therapeutics Market
Accounted market size in year	US$ 52090 million
Forecasted market size in 2031	US$ 69660 million
CAGR	4.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Lysosomal Storage Diseases Diabetes Obesity Inherited Metabolic Disorders Hypercholesterolemia
Segment by Application	Oral Parenteral Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disorder Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Metabolic Disorder Therapeutics Market growing?

Ans: The Metabolic Disorder Therapeutics Market witnessing a CAGR of 4.3% during the forecast period 2025-2031.

What is the Metabolic Disorder Therapeutics Market size in 2031?

Ans: The Metabolic Disorder Therapeutics Market size in 2031 will be US$ 69660 million.

Who are the main players in the Metabolic Disorder Therapeutics Market report?

Ans: The main players in the Metabolic Disorder Therapeutics Market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc.

What are the Application segmentation covered in the Metabolic Disorder Therapeutics Market report?

Ans: The Applications covered in the Metabolic Disorder Therapeutics Market report are Oral, Parenteral, Others

What are the Type segmentation covered in the Metabolic Disorder Therapeutics Market report?

Ans: The Types covered in the Metabolic Disorder Therapeutics Market report are Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia

Recommended Reports

Metabolic Disorders

Rare & Genetic Disease

Neurology & Mental Health

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Lysosomal Storage Diseases

1.2.3 Diabetes

1.2.4 Obesity

1.2.5 Inherited Metabolic Disorders

1.2.6 Hypercholesterolemia

1.3 Market by Application

1.3.1 Global Metabolic Disorder Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oral

1.3.3 Parenteral

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Metabolic Disorder Therapeutics Market Perspective (2020-2031)

2.2 Global Metabolic Disorder Therapeutics Growth Trends by Region

2.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Metabolic Disorder Therapeutics Market Dynamics

2.3.1 Metabolic Disorder Therapeutics Industry Trends

2.3.2 Metabolic Disorder Therapeutics Market Drivers

2.3.3 Metabolic Disorder Therapeutics Market Challenges

2.3.4 Metabolic Disorder Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue

3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Metabolic Disorder Therapeutics Revenue

3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio

3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2024

3.5 Global Key Players of Metabolic Disorder Therapeutics Head office and Area Served

3.6 Global Key Players of Metabolic Disorder Therapeutics, Product and Application

3.7 Global Key Players of Metabolic Disorder Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Disorder Therapeutics Breakdown Data by Type

4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2026-2031)

5 Metabolic Disorder Therapeutics Breakdown Data by Application

5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Metabolic Disorder Therapeutics Market Size (2020-2031)

6.2 North America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Metabolic Disorder Therapeutics Market Size by Country (2020-2025)

6.4 North America Metabolic Disorder Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Metabolic Disorder Therapeutics Market Size (2020-2031)

7.2 Europe Metabolic Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025)

7.4 Europe Metabolic Disorder Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Metabolic Disorder Therapeutics Market Size (2020-2031)

9.2 Latin America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Metabolic Disorder Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novo Nordisk A/S

11.1.1 Novo Nordisk A/S Company Details

11.1.2 Novo Nordisk A/S Business Overview

11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction

11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.1.5 Novo Nordisk A/S Recent Development

11.2 Sanofi S.A.

11.2.1 Sanofi S.A. Company Details

11.2.2 Sanofi S.A. Business Overview

11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction

11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.2.5 Sanofi S.A. Recent Development

11.3 Boehringer Ingelheim GmbH

11.3.1 Boehringer Ingelheim GmbH Company Details

11.3.2 Boehringer Ingelheim GmbH Business Overview

11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction

11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.3.5 Boehringer Ingelheim GmbH Recent Development

11.4 Eli Lilly and Company

11.4.1 Eli Lilly and Company Company Details

11.4.2 Eli Lilly and Company Business Overview

11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction

11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.4.5 Eli Lilly and Company Recent Development

11.5 Merck KgaA

11.5.1 Merck KgaA Company Details

11.5.2 Merck KgaA Business Overview

11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction

11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.5.5 Merck KgaA Recent Development

11.6 Amgen, Inc.

11.6.1 Amgen, Inc. Company Details

11.6.2 Amgen, Inc. Business Overview

11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction

11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.6.5 Amgen, Inc. Recent Development

11.7 AstraZeneca PLC

11.7.1 AstraZeneca PLC Company Details

11.7.2 AstraZeneca PLC Business Overview

11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction

11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.7.5 AstraZeneca PLC Recent Development

11.8 Actelion Pharmaceuticals Ltd.

11.8.1 Actelion Pharmaceuticals Ltd. Company Details

11.8.2 Actelion Pharmaceuticals Ltd. Business Overview

11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction

11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.8.5 Actelion Pharmaceuticals Ltd. Recent Development

11.9 Shire PLC

11.9.1 Shire PLC Company Details

11.9.2 Shire PLC Business Overview

11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction

11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.9.5 Shire PLC Recent Development

11.10 AbbVie, Inc.

11.10.1 AbbVie, Inc. Company Details

11.10.2 AbbVie, Inc. Business Overview

11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction

11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.10.5 AbbVie, Inc. Recent Development

11.11 Biocon Ltd.

11.11.1 Biocon Ltd. Company Details

11.11.2 Biocon Ltd. Business Overview

11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction

11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.11.5 Biocon Ltd. Recent Development

11.12 BioMarin Pharmaceutical, Inc.

11.12.1 BioMarin Pharmaceutical, Inc. Company Details

11.12.2 BioMarin Pharmaceutical, Inc. Business Overview

11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction

11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.12.5 BioMarin Pharmaceutical, Inc. Recent Development

11.13 Bristol-Myers Squibb Company

11.13.1 Bristol-Myers Squibb Company Company Details

11.13.2 Bristol-Myers Squibb Company Business Overview

11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction

11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.13.5 Bristol-Myers Squibb Company Recent Development

11.14 Cipla, Inc.

11.14.1 Cipla, Inc. Company Details

11.14.2 Cipla, Inc. Business Overview

11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction

11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.14.5 Cipla, Inc. Recent Development

11.15 CymaBay Therapeutics, Inc.

11.15.1 CymaBay Therapeutics, Inc. Company Details

11.15.2 CymaBay Therapeutics, Inc. Business Overview

11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction

11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025)

11.15.5 CymaBay Therapeutics, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novo Nordisk A S

Sanofi

Boehringer Ingelheim GmbH

Eli Lilly and Company

Merck KGaA

Amgen Inc

Astrazeneca plc

Actelion Pharmaceuticals Ltd

Shire Plc

AbbVie

Biocon Ltd.

BioMarin Pharmaceutical Inc

Bristol Myers Squibb Company

Cipla Ltd

CymaBay Therapeutics Inc

List of Tables

Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Lysosomal Storage Diseases

Table 3. Key Players of Diabetes

Table 4. Key Players of Obesity

Table 5. Key Players of Inherited Metabolic Disorders

Table 6. Key Players of Hypercholesterolemia

Table 7. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Metabolic Disorder Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Metabolic Disorder Therapeutics Market Share by Region (2020-2025)

Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Metabolic Disorder Therapeutics Market Share by Region (2026-2031)

Table 13. Metabolic Disorder Therapeutics Market Trends

Table 14. Metabolic Disorder Therapeutics Market Drivers

Table 15. Metabolic Disorder Therapeutics Market Challenges

Table 16. Metabolic Disorder Therapeutics Market Restraints

Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Metabolic Disorder Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2024)

Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Metabolic Disorder Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Metabolic Disorder Therapeutics, Product and Application

Table 24. Global Key Players of Metabolic Disorder Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Metabolic Disorder Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2020-2025)

Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2026-2031)

Table 34. North America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Metabolic Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Metabolic Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Metabolic Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Metabolic Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. Novo Nordisk A/S Company Details

Table 50. Novo Nordisk A/S Business Overview

Table 51. Novo Nordisk A/S Metabolic Disorder Therapeutics Product

Table 52. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 53. Novo Nordisk A/S Recent Development

Table 54. Sanofi S.A. Company Details

Table 55. Sanofi S.A. Business Overview

Table 56. Sanofi S.A. Metabolic Disorder Therapeutics Product

Table 57. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 58. Sanofi S.A. Recent Development

Table 59. Boehringer Ingelheim GmbH Company Details

Table 60. Boehringer Ingelheim GmbH Business Overview

Table 61. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product

Table 62. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Boehringer Ingelheim GmbH Recent Development

Table 64. Eli Lilly and Company Company Details

Table 65. Eli Lilly and Company Business Overview

Table 66. Eli Lilly and Company Metabolic Disorder Therapeutics Product

Table 67. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Eli Lilly and Company Recent Development

Table 69. Merck KgaA Company Details

Table 70. Merck KgaA Business Overview

Table 71. Merck KgaA Metabolic Disorder Therapeutics Product

Table 72. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 73. Merck KgaA Recent Development

Table 74. Amgen, Inc. Company Details

Table 75. Amgen, Inc. Business Overview

Table 76. Amgen, Inc. Metabolic Disorder Therapeutics Product

Table 77. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 78. Amgen, Inc. Recent Development

Table 79. AstraZeneca PLC Company Details

Table 80. AstraZeneca PLC Business Overview

Table 81. AstraZeneca PLC Metabolic Disorder Therapeutics Product

Table 82. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 83. AstraZeneca PLC Recent Development

Table 84. Actelion Pharmaceuticals Ltd. Company Details

Table 85. Actelion Pharmaceuticals Ltd. Business Overview

Table 86. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product

Table 87. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 88. Actelion Pharmaceuticals Ltd. Recent Development

Table 89. Shire PLC Company Details

Table 90. Shire PLC Business Overview

Table 91. Shire PLC Metabolic Disorder Therapeutics Product

Table 92. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 93. Shire PLC Recent Development

Table 94. AbbVie, Inc. Company Details

Table 95. AbbVie, Inc. Business Overview

Table 96. AbbVie, Inc. Metabolic Disorder Therapeutics Product

Table 97. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 98. AbbVie, Inc. Recent Development

Table 99. Biocon Ltd. Company Details

Table 100. Biocon Ltd. Business Overview

Table 101. Biocon Ltd. Metabolic Disorder Therapeutics Product

Table 102. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 103. Biocon Ltd. Recent Development

Table 104. BioMarin Pharmaceutical, Inc. Company Details

Table 105. BioMarin Pharmaceutical, Inc. Business Overview

Table 106. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product

Table 107. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 108. BioMarin Pharmaceutical, Inc. Recent Development

Table 109. Bristol-Myers Squibb Company Company Details

Table 110. Bristol-Myers Squibb Company Business Overview

Table 111. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product

Table 112. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 113. Bristol-Myers Squibb Company Recent Development

Table 114. Cipla, Inc. Company Details

Table 115. Cipla, Inc. Business Overview

Table 116. Cipla, Inc. Metabolic Disorder Therapeutics Product

Table 117. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 118. Cipla, Inc. Recent Development

Table 119. CymaBay Therapeutics, Inc. Company Details

Table 120. CymaBay Therapeutics, Inc. Business Overview

Table 121. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product

Table 122. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2020-2025) & (US$ Million)

Table 123. CymaBay Therapeutics, Inc. Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

Table 127. Authors List of This Report

List of Figures

Figure 1. Metabolic Disorder Therapeutics Picture

Figure 2. Global Metabolic Disorder Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Metabolic Disorder Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Lysosomal Storage Diseases Features

Figure 5. Diabetes Features

Figure 6. Obesity Features

Figure 7. Inherited Metabolic Disorders Features

Figure 8. Hypercholesterolemia Features

Figure 9. Global Metabolic Disorder Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Metabolic Disorder Therapeutics Market Share by Application: 2024 VS 2031

Figure 11. Oral Case Studies

Figure 12. Parenteral Case Studies

Figure 13. Others Case Studies

Figure 14. Metabolic Disorder Therapeutics Report Years Considered

Figure 15. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Metabolic Disorder Therapeutics Market Share by Region: 2024 VS 2031

Figure 18. Global Metabolic Disorder Therapeutics Market Share by Players in 2024

Figure 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2024

Figure 21. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Metabolic Disorder Therapeutics Market Share by Country (2020-2031)

Figure 23. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Metabolic Disorder Therapeutics Market Share by Country (2020-2031)

Figure 27. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Region (2020-2031)

Figure 35. China Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Metabolic Disorder Therapeutics Market Share by Country (2020-2031)

Figure 43. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Country (2020-2031)

Figure 47. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Metabolic Disorder Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 51. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 52. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 53. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 54. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 55. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 56. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 57. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 58. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 59. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 60. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 61. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 63. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 64. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Blood Pressure Disorders Drug Market Insights Forecast to 2030

Global Osteoporosis Treatment Market Insights Forecast to 2030

Global Drug Delivery in Cancer Market Insights Forecast to 2030

Global Drug Discovery Assays Market Insights Forecast to 2030

Global Systemic Lupus Erythematosus Treatment Market Insights Forecast to 2030

Global Systemic Inflammatory Response Syndrome Treatment Market Insights Forecast to 2030

Global Atherosclerosis Drugs Market Insights Forecast to 2030

Global Mental Health Technology Market Insights Forecast to 2030

Global Benign Prostatic Hyperplasia Treatment Market Insights Forecast to 2030

Global Diabetic Neurological Disorder Therapeutic Drug Market Insights Forecast to 2030

Global Diabetic Tests Market Insights Forecast to 2030

Global Pharmaceutical Contract Development and Manufacturing Market Insights Forecast to 2030

Global Acute Agitation and Aggression Treatment Market Insights Forecast to 2030

Global Nasal Polyps Treatment Market Insights Forecast to 2030

Global Mental Health Care Software and Services Market Insights Forecast to 2030

Global Anaerobic Digestion Plants Market Insights Forecast to 2030

Global Metastatic Colorectal Cancer Drug Market Insights Forecast to 2030

Global Angioedema Treatment Market Insights Forecast to 2030

Global Patient Intake Software Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions